EU Legislators Firm Up Commission’s Plans To Overhaul Pharma Rules
Parliamentary Report Gets Mixed Reception From Industry
Executive Summary
Efforts to overhaul the EU pharmaceutical legislation have been given added impetus after the European Parliament called for action to boost innovation and medicines access, shore up manufacturing and supply chains, and examine the link between R&D spending and drug prices.
You may also be interested in...
EU’s Northern Ireland Drug Supply Solution Imminent
The European Commission’s legislative proposal will close the gaps in medicines regulation caused by Brexit and the Northern Ireland Protocol.
New EU Portal To Track Pricing & Reimbursement Applications
To improve patient access to approved drugs, European R&D-based companies have pledged to apply for pricing and reimbursement of drugs in all EU member states within two years of product approval. A new portal set up by EFPIA will track the progress of these applications, documenting reasons for pricing delays and barriers.
EU’s Northern Ireland Drug Supply Solution Imminent
The European Commission’s legislative proposal will close the gaps in medicines regulation caused by Brexit and the Northern Ireland Protocol.